Safety of percutaneous renal cryoablation: an international multicentre experience from the EuRECA retrospective percutaneous database
- 18 Downloads
To investigate the safety profile of percutaneous cryoablation of renal tumours < 7 cm, utilising data extracted from an international multicentre registry.
Materials and methods
A retrospective review of all immediate and delayed complications from a multicentre database was performed and was categorised according to the Clavien-Dindo classification. Statistical analysis was performed for both overall complications (all Clavien-Dindo) and major complications (Clavien-Dindo 3 to 5). The following criteria were identified as potential predictive factors for complications: centre number, modality of image guidance, tumour size (≤ 4 cm vs. > 4 cm), number of tumours treated in the same session (1 vs. > 1) and tumour histology.
A total of 713 renal tumours underwent ablation in 647 individual sessions. In 596 of the cases, one tumour was treated; in the remaining 51 cases, several tumours were treated per session. Mean lesion size was 2.8 cm. Fifty-four complications (Clavien-Dindo 1 to 5) occurred as a result of the 647 procedures, corresponding to an overall complication rate of 8.3%. The most frequent complication was bleeding (3.2%), with 9 cases (1.4%) requiring subsequent treatment. The rate of major complication was 3.4%. The only statistically significant prognostic factor for a major complication was a tumour size > 4 cm.
Percutaneous renal cryoablation is associated with a low rate of complications. Tumours measuring more than 4 cm are associated with a higher risk of major complications.
• Percutaneous kidney cryoablation has a low rate of complications.
• Bleeding is the most frequent complication.
• A tumour size superior to 4 cm is a predictive factor of major complication.
KeywordsKidney Cryoablation Complications Bleeding
European Registry for Renal Cryoablation
Magnetic resonance imaging
Renal cell carcinomas
The authors state that this work has not received any funding.
Compliance with ethical standards
The scientific guarantor of this publication is Julien Garnon—University Hospital of Strasbourg.
Conflict of interest
Dr. Garnon is a proctor for BTG Galil and received fees for oral presentation for Medtronic and Canon. Dr. Van Strijen, Lagerweld and Breen are proctors for BTG Galil. All other authors have no conflict of interest.
Statistics and biometry
Dr. Rousseau has significant statistical expertise.
Written informed consent was obtained from all subjects (patients) in this study.
Institutional Review Board approval was not required because of the retrospective design of the study.
Study subjects or cohorts overlap
Some study subjects or cohorts have been previously reported in:
• Buy X, Lang H, Garnon J, Sauleau E, Roy C, Gangi A. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol. 2013 Dec;201(6):1353–61. https://doi.org/10.2214/AJR.13.11084.
• Breen DJ, Bryant TJ, Abbas A, Shepherd B, McGill N, Anderson JA, Lockyer RC,Hayes MC, George SL. Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int. 2013 Oct;112(6):758–65. https://doi.org/10.1111/bju.12122.
• multicentre study
- 1.Uhlig J, Strauss A, Rücker G et al (2018) Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. Eur Radiol. https://doi.org/10.1007/s00330-018-5660-3
- 6.Buy X, Lang H, Garnon J, Gangi A (2011) Percutaneous ablation of renal tumors: radiofrequency ablation or cryoablation? Journal de Radiologie 92(9):774–788. https://doi.org/10.1016/j.jradio.2011.07.016
- 23.Bagley DH, Terrill R, Javadpour N, Beazley RM (1976) Cryosurgery of the ureter in dogs. Invest Urol 14(3):241–245Google Scholar